Intragastric balloon for obesity treatment: Systematic review and meta-analysis of randomized controlled trials

Abstract

Background and study aims

Intragastric balloon (IGB) is a minimally invasive and reversible endoscopic option for treating obesity. This systematic review and meta-analysis compared the effectiveness of IGB versus standard medical therapy (SMT) for obesity management, including studies with a minimum treatment duration of 6 months. Subgroup analyses were performed based on IGB type, baseline mean body mass index (BMI), and use of pharmacological therapy in the SMT group.

Methods

We searched for randomized controlled trials (RCTs) in MEDLINE, EMBASE, and Cochrane Library databases. Outcomes were evaluated at 6, 9, and 12 months after initiation of treatment. A random-effects model was used to calculate the pooled mean difference (MD) with 95% confidence interval (CI) for continuous outcomes.

Results

We included 15 RCTs (1961 patients). Compared with SMT, IGB significantly improved the percentage of excess weight loss at 6 months (MD 16.80; 95% CI 9.22–24.38), 9 months (MD 14.36; 95% CI 7.67–21.04), and 12 months (MD 13.10; 95% CI 10.43–15.77). IGB also showed superior results in percentage of total weight loss, absolute weight loss, and BMI reduction at all time points compared with SMT. There were significant subgroup differences for some outcomes according to IGB type and baseline mean BMI.

Conclusions

In obese adults, IGB is more effective than SMT for weight loss at 6, 9, and 12 months.

Keywords

Endoscopy Upper GI Tract - Statistics - Epidemiology

Publikationsverlauf

Eingereicht: 14. Januar 2025

Angenommen nach Revision: 05. August 2025

Accepted Manuscript online:
11. August 2025

Artikel online veröffentlicht:
03. September 2025

• References

• 1 Ward ZJ, Bleich SN, Cradock AL. et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med 2019; 381: 2440-2450
• 2 World Health Organization. Obesity and overweight. 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
• 3 Ribaric G, Buchwald JN, McGlennon TW. Diabetes and weight in comparative studies of bariatric surgery vs conventional medical therapy: a systematic review and meta-analysis. Obes Surg 2014; 24: 437-455
• 4 Fehervari M, Fadel MG, Alghazawi LOK. et al. Medium-term weight loss and remission of comorbidities following endoscopic sleeve gastroplasty: A systematic review and meta-analysis. Obes Surg 2023; 33: 3527-3538
• 5 Chang SH, Stoll CR, Song J. et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg 2014; 149: 275-287
• 6 English WJ, DeMaria EJ, Brethauer SA. et al. American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016. Surg Obes Relat Dis 2018; 14: 259-263
• 7 Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology 2017; 152: 1791-1801
• 8 Stavrou G, Shrewsbury A, Kotzampassi K. Six intragastric balloons: Which to choose?. World J Gastrointest Endosc 2021; 13: 238-259
• 9 Saber AA, Shoar S, Almadani MW. et al. Efficacy of first-time intragastric balloon in weight loss: a systematic review and meta-analysis of randomized controlled trials. Obes Surg 2017; 27: 277-287
• 10 Vyas D, Deshpande K, Pandya Y. Advances in endoscopic balloon therapy for weight loss and its limitations. World J Gastroenterol 2017; 23: 7813-7817
• 11 Moura D, Oliveira J, De Moura EG. et al. Effectiveness of intragastric balloon for obesity: A systematic review and meta-analysis based on randomized control trials. Surg Obes Relat Dis 2016; 12: 420-429
• 12 Kotinda APST, de Moura DTH, Ribeiro IB. et al. Efficacy of intragastric balloons for weight loss in overweight and obese adults: A systematic review and meta-analysis of randomized controlled trials. Obes Surg 2020; 30: 2743-2753
• 13 Higgins J, Thomas J, Chandler J. et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane 2022. https://www.training.cochrane.org/handbook
• 14 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
• 15 Sterne JAC, Savović J, Page MJ. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898
• 16 Lau J, Ioannidis JP, Terrin N. et al. The case of the misleading funnel plot. BMJ 2006; 333: 597-600
• 17 Schünemann HJ, Oxman AD, Brozek J. et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336: 1106-1110
• 18 Luo D, Wan X, Liu J. et al. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res 2018; 27: 1785-1805
• 19 Wan X, Wang W, Liu J. et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135
• 20 Farina MG, Baratta R, Nigro A. et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg 2012; 22: 565-571
• 21 Fuller NR, Pearson S, Lau NS. et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity (Silver Spring) 2013; 21: 1561-1570
• 22 Kashani AF, Forghani F, Mokhtare M. et al. Comparing intragastric balloon placement with low calorie diet in short-term weight loss. SN Compr Clin Med 2022; 4: 224
• 23 Mohammed MA, Anwar R, Mansour AH. et al. Effects of intragastric balloon versus conservative therapy on appetite regulatory hormones in obese subjects. Trends Med Res 2014; 9: 58-80
• 24 Ponce J, Woodman G, Swain J. et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis 2015; 11: 874-881
• 25 Sullivan S, Swain J, Woodman G. et al. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss. Surg Obes Relat Dis 2018; 14: 1876-1889
• 26 Vicente Martin C, Rabago Torre LR, Castillo Herrera LA. et al. Preoperative intragastric balloon in morbid obesity is unable to decrease early postoperative morbidity of bariatric surgery (sleeve gastrectomy and gastric bypass): a clinical assay. Surg Endosc 2020; 34: 2519-2531
• 27 Courcoulas A, Abu Dayyeh BK, Eaton L. et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes (Lond) 2017; 41: 427-433
• 28 Gómez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: Results of a prospective study. Obesity (Silver Spring) 2016; 24: 1849-1853
• 29 Hollenbach M, Prettin C, Gundling F. et al. Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure. BMC Gastroenterol 2018; 18: 118
• 30 Abu Dayyeh BK, Maselli DB, Rapaka B. et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet 2021; 398: 1965-1973
• 31 Lee YM, Low HC, Lim LG. et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc 2012; 76: 756-760
• 32 Chan DL, Cruz JR, Mui WL. et al. Outcomes with intra-gastric balloon therapy in BMI < 35 non-morbid obesity: 10-year follow-up study of an RCT. Obes Surg 2021; 31: 781-786
• 33 Konopko-Zubrzycka M, Baniukiewicz A, Wróblewski E. et al. The effect of intragastric balloon on plasma ghrelin, leptin, and adiponectin levels in patients with morbid obesity. J Clin Endocrinol Metab 2009; 94: 1644-1649
• 34 Coffin B, Maunoury V, Pattou F. et al. Impact of intragastric balloon before laparoscopic gastric bypass on patients with super obesity: A randomized multicenter study. Obes Surg 2017; 27: 902-909
• 35 Muniraj T, Day LW, Teigen LM. et al. AGA Clinical Practice Guidelines on Intragastric Balloons in the Management of Obesity. Gastroenterology 2021; 160: 1799-1808
• 36 Jirapinyo P, Hadefi A, Thompson CC. et al. American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity. Endoscopy 2024; 56: 437-456
• 37 Karakasis P, Fragakis N, Patoulias D. et al. The emerging role of glucagon-like peptide-1 receptor agonists in the management of obesity-related heart failure with preserved ejection fraction: Benefits beyond what scales can measure?. Biomedicines 2024; 12: 2112
• 38 Martines G, Dezi A, Giove C. et al. Efficacy of intragastric balloon versus liraglutide as bridge to surgery in super-obese patients. Obes Facts 2023; 16: 457-464
• 39 Yilmaz A, Hanlioğlu S, Demiral G. et al. The efficacy of liraglutide combined with intragastric balloon on weight loss. Rev Assoc Med Bras 2023; 69: e20230571